Key statistics
On Friday, Nuvalent Inc (NUVL:NSQ) closed at 108.00, -4.85% below its 52-week high of 113.51, set on Sep 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 103.99 |
---|---|
High | 108.98 |
Low | 102.72 |
Bid | 43.20 |
Offer | 109.97 |
Previous close | 103.25 |
Average volume | 1.06m |
---|---|
Shares outstanding | 65.27m |
Free float | 55.43m |
P/E (TTM) | -- |
Market cap | 7.05bn USD |
EPS (TTM) | -2.78 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Nuvalent Announces Closing of Upsized Public Offering of Common Stock
- Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
- Nuvalent Announces Public Offering of Common Stock
- Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
- Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655
- Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles
- Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results
- Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor
- Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024
More ▼